Project Grant R01CA276347
- The National Institutes of Health's National Cancer Institute awarded a $283,136 Project Grant to the Regents of the University of Michigan under the Cancer Research Manpower federal grant program (CFDA 93.398). The award will support research investigating cellular communication in the tumor microenvironment of pancreatic cancer. The grantee will examine how hedgehog signaling alters the immune landscape and endothelial cell function through fibroblast interactions. They will also determine the...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded The Leland Stanford Junior University a Project Grant totaling $209,177 (Award Date: February 1, 2026; Completion Date: January 31, 2031) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). This research initiative focuses on investigating the MAP4K4 (Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4) pathway as a...
- The University of Michigan received a $214,993 Project Grant award from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398), with an award date of August 14, 2025 and completion date of February 29, 2028. The grant funds research aimed at establishing PIKFYVE (phosphatidylinositol 3-phosphate 5-kinase) inhibition as a therapeutic strategy for pancreatic ductal adenocarcinoma (PDAC), a disease that depends on lysosome-mediated nutrient recycling in its...
- This $370,575 project grant from the National Institutes of Health National Cancer Institute Cancer Biology Research program (CFDA 93.396) will fund research at the University of Cincinnati investigating the molecular mechanisms of growth in pancreatic cancer with GNAS mutations. The grant supports studies from August 1, 2022 to July 31, 2027 to further the understanding of the oncogenic functions of mutant GNAS and its downstream signaling pathways. Specifically, the research will illuminate...
- The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $451,000 Project Grant to The Regents of the University of California, San Francisco on August 8, 2025, under the Oral Diseases and Disorders Research program (CFDA 93.121). This award supports the development and comprehensive characterization of metastatic MYB-NFIB fusion adenoid cystic carcinoma (ACC) cell line models through August 7, 2027. The research addresses a critical clinical need, as ACC is a rare but...
- Summary of Cooperative Agreement Award The National Cancer Institute (NCI) awarded a $1.28 million Cooperative Agreement under the Cancer Biology Research program (CFDA 93.396) to The Leland Stanford Junior University on July 25, 2025, for research spanning through May 31, 2030. The research initiative, titled "Multiplexed Dissection of Metastatic Ability, Organ Tropism, and Immune Evasion," focuses on understanding how diverse pancreatic ductal adenocarcinoma (PDAC) cell states...
- This $946,540 project grant from the National Cancer Institute, part of the Department of Health and Human Services, supports research under the Cancer Treatment Research program. Health Research-Roswell Park Cancer Institute Division will target HNF1A-mediated therapeutic resistance in pancreatic ductal adenocarcinoma. The researchers will characterize regulation of the HNF1A gene by the BRD4 protein and establish bromodomain inhibitors as a means to overcome HNF1A-mediated resistance to KRAS...
- Federal Project Grant Summary Fred Hutchinson Cancer Center received a $739,640 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) awarded September 1, 2025, through August 31, 2030. The award supports research to develop and advance early detection methods for pancreatic ductal adenocarcinoma (PDAC) by leveraging electronic medical records (EMR) data. The project builds on prior collaborative findings demonstrating that...
- Federal Project Grant Summary The University of Pennsylvania received a $126,220 Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), effective September 10, 2025, with completion targeted for May 31, 2026. This award supports biomedical research training and career development in cancer research aligned with the National Cancer Program's strategic priorities. The funded research, titled "Mechanisms of Lymphatic Metastasis in...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $136,266 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) effective July 14, 2025, through June 30, 2027. The grant funds research aimed at identifying therapeutic strategies to prevent small cell lung cancer (SCLC) histological transformation in epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma patients. The research focuses on understanding the...
DISSECTING ROLES OF LUNATIC FRINGE-DEPENDENT NOTCH SIGNALING IN PANCREATIC CANCER - DESPITE IMPROVEMENTS IN OVERALL SURVIVAL FOR MOST CANCERS, SURVIVAL FOR PATIENTS WITH PANCREATIC CANCER REMAINS DISMALLY LOW DUE TO THE LATE DIAGNOSIS AND RAPID SPREADING. UNDERSTANDING PANCREATIC CANCER INITIATION AND PROGRESSION IS OF GREAT IMPORTANCE FOR THE DEVELOPMENT OF EFFECTIVE INTERVENTION STRATEGY. MOUSE MODELS RECAPITULATING HUMAN PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) HAVE BEEN GENERATED THROUGH ACTIVATION OF ONCOGENIC KRAS COMBINED WITH VARIOUS GENETIC MUTATIONS IN DIFFERENT PANCREATIC CELL TYPES, AND STUDIES USING MOUSE GENETICS SUGGEST THAT BOTH ACINAR AND DUCTAL CELLS CAN GIVE RISE TO PDAC, AND CELLULAR ORIGINS AND SPECIFIC GENE MUTATIONS MAY DETERMINE THE PRECURSOR LESION INITIATION, PROGRESSION, AS WELL AS MOLECULAR SUBTYPE OF PDAC. NOTCH SIGNALING PATHWAY IS A MASTER REGULATOR OF CELL FATE DECISION AND DIFFERENTIATION CRITICAL FOR PANCREATIC DEVELOPMENT AND IS DYSREGULATED IN PANCREATIC CANCER. WE RECENTLY DISCOVERED THAT EXPRESSION OF A NOTCH MODULATOR, LUNATIC FRINGE (LFNG), IS CONFINED TO A SUBSET OF CENTROACINAR CELLS IN THE NORMAL PANCREAS. LFNG-EXPRESSING CENTROACINAR CELLS ARE UNIQUELY SUSCEPTIBLE TO ONCOGENIC TRANSFORMATION AND DELETION OF LFNG BLOCKS TUMOR INITIATION FROM THESE CELLS. LFNG IS UPREGULATED IN ACINAR AND DUCTAL CELL-DERIVED PRECURSOR LESIONS, AND DELETION OF LFNG DECELERATES TUMOR DEVELOPMENT FROM THESE TWO CELL TYPES. THUS, LFNG EXERTS ONCOGENIC ROLES IN THE DEVELOPMENT OF PDAC FROM THREE DISTINCT CELLULAR ORIGINS: CENTROACINAR, ACINAR AND DUCTAL CELLS. AMPLIFICATION AND UPREGULATION OF LFNG ARE NOTED IN HUMAN PDAC AND ARE ASSOCIATED WITH POOR SURVIVAL. THEREFORE, WE PROPOSE TO DISSECT ROLES OF LFNG-DEPENDENT NOTCH SIGNALING IN PANCREATIC CANCER USING MULTIPLE APPROACHES INCLUDING ORGANOID CULTURE, LINEAGE TRACING, TEMPORAL AND LINEAGE-SPECIFIC GENETIC MANIPULATIONS, DIFFERENTIAL GENE EXPRESSION ANALYSIS, AS WELL AS FUNCTIONAL ANALYSIS OF CANDIDATE GENES IN HUMAN PDAC CELL LINES TO ADDRESS THE FOLLOWING SPECIFIC AIMS: 1) DETERMINE ROLES OF LFNG-DEPENDENT NOTCH SIGNALING IN PANCREATIC CANCER DEVELOPMENT FROM LFNG- EXPRESSING CENTROACINAR CELLS; 2) DETERMINE ROLES OF LFNG-DEPENDENT NOTCH SIGNALING IN ACINAR- AND DUCTAL-DERIVED PDAC PATHOGENESIS; AND 3) CHARACTERIZE LFNG-EXPRESSING PANCREATIC CANCER CELLS AND IDENTIFY GENES DIFFERENTIALLY EXPRESSED IN THESE CELLS AS POTENTIAL THERAPEUTIC TARGETS. WE HOPE TO DEMONSTRATE THAT LFNG IS CRITICAL FOR THE INITIATION AND PROGRESSION OF PANCREATIC CANCERS ARISING FROM DIFFERENT CELL TYPES OF THE PANCREAS, AND THAT LFNG MARKS PANCREATIC CANCER STEM CELLS THOUGHT TO BE RESPONSIBLE FOR DRUG RESISTANCE AND CANCER RELAPSE. IDENTIFICATION OF GENES DOWNSTREAM OF LFNG-DEPENDENT NOTCH SIGNALING MAY LEAD TO THE DEVELOPMENT OF BIOMARKERS FOR TARGETED THERAPY FOR THIS PARTICULARLY DEADLY DISEASE.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $35.5k | 6/6/25 | ||
| Not listed | $319.1k | 4/11/25 | ||
| Not listed | $319.1k | 4/11/25 | ||
| Not listed | $354.6k | 4/16/24 | ||
| Not listed | $354.6k | 4/16/24 |